| 摘要 |
NZ 597080 Disclosed is the use of rifaximin for the preparation of a medicament for reducing the risk of overt hepatic encephalopathy (HE) occurrence in a subject, wherein the medicament is formulated for administration between 1000 and 1200 mg of rifaximin daily to the subject if his or her Child-Pugh score is Child-Pugh Class C. |
